At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALT Altimmune, Inc.
Trading 06-29 14:01:56 EDT
2.89
+0.07
+2.30%
High2.90Low2.79Vol1.76M
Open2.85D1 Closing2.82Amplitude3.90%
Mkt Cap559.69MTradable Cap536.61MTotal Shares194.00M
T/O4.99MT/O Rate0.95%Tradable Shares186.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unusually active option classes on open June 24th
TIPRANKS  ·  06-24
Unusually active option classes on open June 24th
Altimmune Initiated at Outperform by Leerink Partners
Dow Jones  ·  06-22
Altimmune Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Altimmune at Outperform With $10 Price Target
MT Newswires Live  ·  06-22
Leerink Partners Initiates Altimmune at Outperform With $10 Price Target
Altimmune Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $10
THOMSON REUTERS  ·  06-22
Altimmune Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $10
Altimmune initiated with an Outperform at Leerink
TIPRANKS  ·  06-22
Altimmune initiated with an Outperform at Leerink
U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon
Reuters  ·  06-22
U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon
Altimmune plans to move headquarters to Morristown, New Jersey from Maryland
Reuters  ·  06-17
Altimmune plans to move headquarters to Morristown, New Jersey from Maryland
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
GlobeNewswire  ·  06-11
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Boehringer - 84.2% Patients on Survodutide Cut Liver Fat by at Least 30% VS 24.3% on Placebo in Synchronize-Masld
THOMSON REUTERS  ·  06-08
Boehringer - 84.2% Patients on Survodutide Cut Liver Fat by at Least 30% VS 24.3% on Placebo in Synchronize-Masld
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Reuters  ·  06-08
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Boehringer - Survodutide Drug Showed 34% Visceral and 63% Liver Fat Reduction, Minimized Lean Mass Loss
THOMSON REUTERS  ·  06-08
Boehringer - Survodutide Drug Showed 34% Visceral and 63% Liver Fat Reduction, Minimized Lean Mass Loss
H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
TIPRANKS  ·  06-04
H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
GlobeNewswire  ·  06-03
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
GlobeNewswire  ·  06-01
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
TIPRANKS  ·  05-29
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide
Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients
MT Newswires Live  ·  05-28
Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Icon (ICLR) and AIM ImmunoTech (AIM)
TIPRANKS  ·  05-28
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Icon (ICLR) and AIM ImmunoTech (AIM)
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease
MT Newswires Live  ·  05-27
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease
Altimmune says pemvidutide shows fibrosis regression in MASH in IMPACT Phase 2b qFibrosis analysis
Reuters  ·  05-27
Altimmune says pemvidutide shows fibrosis regression in MASH in IMPACT Phase 2b qFibrosis analysis
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
GlobeNewswire  ·  05-27
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Introduction

Company Name.
Altimmune, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Issue price:
--